Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA


Guest: Shubha Bhat, PharmD

Fortunately, there are a lot of studies that have evaluated biosimilars in inflammatory bowel disease (IBD), and those all confirmed that biosimilars are safe, effective, and do not result in worsening patient outcomes. But are we using biosimilars enough in the treatment of IBD? Dive in with Dr. Mary Katherine Cheeley as she speaks with Dr. Shubha Bhat, Clinical Pharmacist in the Digestive Disease Institute at the Cleveland Clinic.